Skip to main content
. 2022 Oct 6;23(19):11887. doi: 10.3390/ijms231911887

Figure 5.

Figure 5

(A) Co-stimulation of CXCR4/ACKR3 with either EGFR or HER2/3 ligands amplifies ERK1/2 activation in MDA-MB-361 cells (ER+ and HER2+). Cells were serum-starved and stimulated with 10 nM CXCL12, 100 ng/mL EGF, 20 ng/mL Heregulin or the indicated combination of ligands for 2 min. ERK1/2 activation was assessed in cell lysates as in previous figures. Representative blots are shown. Data are mean ± SEM of 4–11 independent experiments. ** p < 0.01, *** p < 0.001 for the indicated comparisons. (B) Pharmacological inhibition of GRK2 markedly attenuates ERK activation promoted by EGF or Heregulin alone or in the simultaneous presence of CXCL12. Serum-starved MDA-MB-361 cells were treated for 2 h with 30µM CMPD101. Afterwards, cells were stimulated with 10 nM CXCL12, 100 ng/mL EGF, 20 ng/mL Heregulin or the indicated combinations for 2 min. ERK1/2 activation was assessed in cell lysates as in previous figures. Representative blots are shown. Blot lanes run on the same gel but non-contiguously are indicated by a black vertical line. Data are mean ± SEM of 4–9 independent experiments. * p < 0.05 for the indicated comparisons.